The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001227381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
8/09/2026
Date registered
Help: Date registered
7/10/2026
Date last updated
Help: Date last updated
7/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/10/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Does having your glucose reading visible on a dashboard-mounted phone make driving safer for people with insulin-treated diabetes?
Scientific title
Effect of a dashboard-mounted real-time continuous glucose monitoring display on glycaemia during driving in adults with insulin-treated diabetes: a randomised crossover trial
Additional trial identifiers [1] 318149 0
NRSAGP Activity ID 4-L1ON32N
Universal Trial Number (UTN)
Trial acronym
NAVI-CGM
Related trial records

Health condition
Health condition(s) studied:
Type 1 diabetes mellitus 343519 0
Type 2 diabetes mellitus 343520 0
Insulin-treated diabetes 343521 0
Hypoglycaemia 343660 0
Condition category
Condition code
Metabolic and Endocrine 339622 339622 0 0
Diabetes
Injuries and Accidents 339623 339623 0 0
Other injuries and accidents
Public Health 339624 339624 0 0
Health promotion/education

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Each participant completes two consecutive one-month periods and acts as their own control. The order of the two periods is randomised.

Intervention period (the "mount" month). Participants are supplied with a dashboard phone mount, which they fit securely in the vehicle they drive most often. Their own smartphone, running their existing continuous glucose monitoring (CGM) application, is placed in the mount whenever they drive, so that their real-time glucose reading is visible at a glance while driving. Participants are asked to keep the display available for the whole month; how often they choose to look at it is left to them. Use of the mounted display is consistent with the Victorian Road Safety Road Rules 2017 (rule 304H), which permit a fully licensed driver to use a securely mounted device for a function designed to monitor the driver's condition, provided no text is entered and the screen is not scrolled. Participants were advised that they may glance at the display and briefly touch it, but must not hold the phone, scroll or type while the vehicle is moving.

Participants continue using their usual CGM device throughout both periods. Those who use a continuous glucose monitor that drives an automated insulin-delivery (closed-loop) system remain on their own device, so that insulin dosing is unaffected. Other participants may either continue on their own device or use a study-supplied Dexcom G7 for the two months. The device used is held constant across a participant's two periods.

Throughout both periods, a GPS trip logger is plugged into the vehicle's 12-volt socket and records the dates, times and routes of journeys, from which the start, end and distance of each trip are derived. Participants also keep a short driving diary to record occasions when another person drove the vehicle.

Duration: two consecutive months per participant (approximately 28 days per period). Delivery is entirely remote, in participants' own vehicles and daily driving; there is no clinic attendance. Adherence to the mounted-display condition is monitored by an end-of-month questionnaire item asking participants to confirm which condition they completed.

Washout period: none. The two periods run consecutively, with the second period beginning the day after the first period ends. A washout was not used because the intervention is the visibility of existing information rather than a pharmacological exposure, and because a gap would have extended participant burden without a physiological rationale. In a two-period, two-sequence crossover, carryover cannot be estimated separately from differences between the two sequence groups, so it is not formally tested and no analysis is chosen on the basis of a carryover test. Every model includes a period term. The sensitivity of the primary result to carryover is examined by repeating the primary analysis with driving in the first seven days of each study month excluded.
Intervention code [1] 335269 0
Treatment: Devices
Intervention code [2] 335270 0
Behaviour
Description of the comparator or control
The comparator is the participant's usual driving practice. During the control month the dashboard mount is not used and the participant does not view a mounted glucose display while driving; they drive exactly as they normally would, managing their diabetes as usual. Participants continue to wear the same CGM device as in the intervention month, and retain their usual glucose alerts on whichever device delivers them (phone, smartwatch, CGM reader or insulin pump). The GPS trip logger and driving diary continue in the same way, so that glucose and driving data are collected identically in both periods. The comparison is therefore within-participant, each participant serving as their own control, with the order of the two periods randomised in permuted blocks.
Control group
Active

Outcomes
Primary outcome [1] 346795 0
Percentage of time spent in the target glucose range (3.9 to 10.0 mmol/L) while driving
Timepoint [1] 346795 0
Calculated across each of the two consecutive one-month study periods (approximately 28 days each) and compared within participant between the mount month and the control month. Assessed at the end of month 1 and the end of month 2 following individual study commencement.
Secondary outcome [1] 467545 0
Percentage of time spent below the target glucose range (below 3.9 mmol/L) while driving
Timepoint [1] 467545 0
Calculated across each of the two consecutive one-month study periods and compared within participant between the mount month and the control month. Assessed at the end of month 1 and the end of month 2 following individual study commencement.
Secondary outcome [2] 467585 0
Self-reported frequency of low glucose episodes experienced while driving
Timepoint [2] 467585 0
End of month 1 and end of month 2 following individual study commencement, compared within participant between the mount month and the control month.
Secondary outcome [3] 467586 0
Acceptability of the in-car glucose display, assessed using the Technology Acceptance Model 2 (TAM2) subscale: perceived usefulness.
Timepoint [3] 467586 0
End of month 1 and end of month 2, relative to each participant's individual study commencement.
Secondary outcome [4] 467587 0
Self-reported near-miss or accident while driving that the participant believes was related to their glucose level.
Timepoint [4] 467587 0
End of month 1 and end of month 2, relative to each participant's individual study commencement, with events also recorded if reported at any point during the two months.
Secondary outcome [5] 467588 0
Awareness of, and response to, glucose alerts while driving.
Timepoint [5] 467588 0
At baseline before commencement, and at the end of each of the two one-month study periods.
Secondary outcome [6] 467589 0
Diabetes-related emotional distress
Timepoint [6] 467589 0
At baseline only, before commencement.
Secondary outcome [7] 468577 0
Acceptability of the in-car glucose display, assessed using the Technology Acceptance Model 2 (TAM2) subscale: perceived ease of use.
Timepoint [7] 468577 0
End of month 1 and end of month 2, relative to each participant's individual study commencement.
Secondary outcome [8] 468580 0
Self-reported occasions of pulling over while driving because of glucose.
Timepoint [8] 468580 0
End of month 1 and end of month 2, relative to each participant's individual study commencement, with events also recorded if reported at any point during the two months.
Secondary outcome [9] 468581 0
Self-reported occasions of driving while suspecting hypoglycaemia and continuing anyway.
Timepoint [9] 468581 0
End of month 1 and end of month 2, relative to each participant's individual study commencement, with events also recorded if reported at any point during the two months.
Secondary outcome [10] 468582 0
Number of self-reported crashes while driving, regardless of fault.
Timepoint [10] 468582 0
End of month 1 and end of month 2, relative to each participant's individual study commencement, with events also recorded if reported at any point during the two months.
Secondary outcome [11] 468583 0
Participants' lived experience of driving with, and without, a mounted glucose display.
Timepoint [11] 468583 0
Once, after completion of both study months and following return of the study equipment.
Secondary outcome [12] 468584 0
Confidence in managing glucose while driving (driving-specific self-efficacy).
Timepoint [12] 468584 0
At baseline before commencement, and at the end of each of the two one-month study periods.
Secondary outcome [13] 468585 0
Impaired awareness of hypoglycaemia.
Timepoint [13] 468585 0
At baseline only, before commencement.
Secondary outcome [14] 468586 0
Acceptability of the in-car glucose display, assessed using the Technology Acceptance Model 2 (TAM2) subscale: behavioural intention to continue use.
Timepoint [14] 468586 0
End of month 1 and end of month 2, relative to each participant's individual study commencement.
Secondary outcome [15] 468587 0
Percentage of time spent above 10.0 mmol/L while driving
Timepoint [15] 468587 0
Calculated across each of the two one-month study periods and compared within participant between the mount month and the control month.
Secondary outcome [16] 468588 0
Percentage of time spent at or below 5.0 mmol/L while driving
Timepoint [16] 468588 0
Calculated across each of the two one-month study periods and compared within participant between the mount month and the control month.
Secondary outcome [17] 468598 0
Percentage of time spent above 13.9 mmol/L while driving
Timepoint [17] 468598 0
Calculated across each of the two one-month study periods and compared within participant between the mount month and the control month.
Secondary outcome [18] 468599 0
Percentage of time spent above 16.7 mmol/L while driving
Timepoint [18] 468599 0
Calculated across each of the two one-month study periods and compared within participant between the mount month and the control month.
Secondary outcome [19] 468600 0
Driving-specific time in range: percentage of time spent with sensor glucose above 5.0 and up to and including 10.0 mmol/L while driving
Timepoint [19] 468600 0
Calculated across each of the two one-month study periods and compared within participant between the mount month and the control month.

Eligibility
Key inclusion criteria
Adults aged 18 years or older who hold a current Victorian driver licence and drive regularly (at least four days per week); have diabetes mellitus treated with insulin; are current users of a continuous glucose monitoring (CGM) system and have used CGM for at least two months; own a smartphone and are comfortable using it to view their CGM data; are proficient in English; and reside in Victoria, Australia.

Participants were recruited from respondents to a preceding national survey conducted by the same research programme who had consented to be contacted about future research, supplemented by participant referral.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Already mounting or viewing a CGM display while driving at the time of recruitment, including via a smartwatch used to access CGM data while driving, since the study requires participants who are not already using an in-car display.

Not holding a current driver licence, not driving regularly, not resident in Victoria, or not using insulin.

Continuous glucose monitoring used for less than two months.

Insufficient English proficiency to complete the questionnaires and interview.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation was not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation was not used. The allocation sequence was computer-generated using randomly permuted blocks of two, so that each block contained one Mount-Month-1 and one Mount-Month-2 allocation in random order. Sixteen blocks were generated, providing 32 allocation slots against a target sample of 25. The sequence was generated on 11 June 2026, before any participant consented or received an allocation, using a seeded pseudorandom number generator in Python; the seed is recorded in the study documentation so the sequence is exactly reproducible. Block size two was chosen to guarantee near-exact balance if recruitment stopped early. The 32 generated slots were balanced 16:16. Of the 30 participants enrolled, 16 were allocated mount-first and 14 mount-second.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
No formal power calculation was performed. A target of 25 participants was set on feasibility
grounds, this being the first real-world study of in-car continuous glucose monitoring display use.
The within-participant crossover design, in which each participant contributes data under both conditions and acts as their own control, provides substantially greater efficiency than a
parallel-group design of the same size.

Recruitment deliberately exceeded the target to protect the analysable sample against attrition, non-starters and incomplete data, which was expected given the two-month duration and the reliance on participant-held equipment. Thirty participants were enrolled (16 allocated mount-first, 14 mount-second).

The primary outcome is analysed as a within-participant comparison between the mount month and the control month using a mixed-effects model including a period term, as is standard for a two-period crossover.

A sensitivity power calculation indicates 80% power to detect a difference of about 11 percentage points in time in range while driving, based on the standard deviations reported by Maeda et al. (2025).

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 322710 0
Government body
Name [1] 322710 0
Australian Government Department of Infrastructure, Transport, Regional Development, Communications and the Arts, through the National Road Safety Action Grants Program (Technology and Innovation stream), Activity ID 4-L1ON32N
Country [1] 322710 0
Australia
Funding source category [2] 322948 0
Commercial sector/Industry
Name [2] 322948 0
Dexcom (in-kind contribution of continuous glucose monitoring sensors and receivers; no financial contribution and no role in study design, conduct, analysis or reporting)
Country [2] 322948 0
Australia
Primary sponsor type
Other Collaborative groups
Name
The Cairnmillar Institute
Address
Country
Australia
Secondary sponsor category [1] 325631 0
University
Name [1] 325631 0
Monash University
Address [1] 325631 0
Country [1] 325631 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321156 0
The Cairnmillar Institute Human Research Ethics Committee
Ethics committee address [1] 321156 0
Ethics committee country [1] 321156 0
Australia
Date submitted for ethics approval [1] 321156 0
05/11/2025
Approval date [1] 321156 0
02/03/2026
Ethics approval number [1] 321156 0
2025110501

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152842 0
A/Prof Steven Trawley
Address 152842 0
The Cairnmillar Institute, 391-393 Tooronga Road, Hawthorn East VIC 3123
Country 152842 0
Australia
Phone 152842 0
+61 497 103 611
Fax 152842 0
Email 152842 0
Contact person for public queries
Name 152843 0
Steven Trawley
Address 152843 0
The Cairnmillar Institute, 391-393 Tooronga Road, Hawthorn East VIC 3123
Country 152843 0
Australia
Phone 152843 0
+61 497 103 611
Fax 152843 0
Email 152843 0
Contact person for scientific queries
Name 152844 0
Steven Trawley
Address 152844 0
The Cairnmillar Institute, 391-393 Tooronga Road, Hawthorn East VIC 3123
Country 152844 0
Australia
Phone 152844 0
+61 497 103 611
Fax 152844 0
Email 152844 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
• Primary outcome(s)
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
30/11/2033
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: Two components of the study dataset will not be shared. Raw GPS trip records are excluded: the study collected timestamped journey records over two months from a small, single-state cohort with an uncommon health condition, and individual journey patterns are potentially identifying even without location coordinates. Only derived driving window summaries are shared. Exit interview recordings and transcripts are also excluded, as qualitative material cannot reliably be de-identified and participants consented to recordings being transcribed and then deleted.

Participants consented to the use of de-identified data in future related research on diabetes,
continuous glucose monitoring or driving safety, provided that research has ethics approval. Sharing is limited to that scope. Requests should include the research question, the analysis proposed, the variables required, evidence of ethics approval, and details of data storage and destruction.
Approved requests are provided under a data sharing agreement prohibiting re-identification and onward transfer.




What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Statistical analysis planNo Phase2_Statistical_Analysis_Plan_v1.2.pdf

Documents added automatically
No additional documents have been identified.